Pharmaceutical & Drug Policy
Incorporating information on therapeutic alternatives into the IRA prescription drug negotiations
Consumers and patients need information about their medications that is accurate, balanced and delivered in an easily understood format. Unfortunately, recent studies have shown that current systems for delivering prescriptions to consumers consistently fail to fulfill the need for pertinent details.
On October 12, the Engelberg Center for Health Care Reform at Brookings hosted a public forum to discuss strategies for ensuring that patients have access to effective patient medication information (PMI). Through a series of panel discussions, key stakeholders explored patients’ expectations for this information and how they access the details and warnings, along with feasible solutions for delivering higher-quality information to patients.
After each panel, speakers took audience questions.
Agenda
-
October 12
-
Welcome, Overview, Key Elements of Effective PMI
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityJWJanet Woodcock Director, Center for Drug Evaluation and Research - US Food and Drug Administration -
9:25 a.m. -- Session I: FDA and Patient Medication Information – The Path Forward
RBRachel Behrman Director, Office of Medical Policy, Center for Drug Evaluation and ResearchAOAmie O’Donoghue Office of Medical Policy, Center for Drug Evaluation and Research, FDA -
10:20 a.m. -- Session II: Patient Perspectives – Making PMI More Effective
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityDPDoris Peter Director, Health Ratings Center - Consumer Health ChoicesNHNancy Hughes Assistant Vice President of Communications and Marketing, National Health CouncilVCVanessa Cajina Statewide Policy Analyst, California Immigrant Policy CenterLRLee Rucker AARP Public Policy Institute, AARPJHJames Heywood Co-Founder and Chairman, PatientsLikeMe -
12:45 p.m. -- Session III: Effective PMI – The Roles of Manufacturers and PMI Vendors
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityTBTom Bizarro Vice President, Health Policy and Industry Relations, First DataBankBBBaxter Byerly Catalina Health ResourceMCMarissa Craddock Manager, Labeling, Advertising, and Promotional Materials, Roxane Laboratories, Inc.FLFreda Lewis-Hall PfizerPBPamela Budny Eli Lilly and Company -
2:25 p.m. -- Session IV: Effective Distribution of PMI
S. Lawrence Kocot Former Brookings Expert, Principal and National Leader, Center for Healthcare Regulatory Insight - KPMGWSWilliam Shrank Harvard Medical School and Brigham & Women's HospitalKBKate Berry Senior Vice President, Strategy and Innovation, SurescriptsWLWill Lockwood Assistant to the Executive Director, American Society for Automation in PharmacyJCJohn Coster Senior Vice President, Government Affairs, National Community Pharmacists AssociationRTRussell Teagarden Vice President, Clinical Practices & Therapeutics, Medco Health Solutions, Inc. -
3:50 p.m. -- Recap and Closing Remarks
RBRachel Behrman Director, Office of Medical Policy, Center for Drug Evaluation and Research
-
